IndexIQ Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

IndexIQ Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$4.58M	Sell	17,542 -395	-2%	-$93.7K	0.16%	123
2021 Q4	$3.94M	Buy	17,937 +195	+1%	+$37.9K	0.13%	135
2021 Q3	$3.22M	Buy	17,742 +19	+0.1%	+$3.71K	0.11%	172
2021 Q2	$3.57M	Sell	17,723 -276	-2%	-$57.7K	0.12%	136
2021 Q1	$3.87M	Buy	17,999 +14,351	+393%	+$3.15M	0.14%	116
2020 Q4	$862K	Buy	3,648 +1,715	+89%	+$393K	0.03%	256
2020 Q3	$526K	Buy	1,933 +1,165	+152%	+$321K	0.02%	261
2020 Q2	$223K	Buy	768 +679	+763%	+$184K	0.01%	469
2020 Q1	$21K	Hold	89	–	–	﹤0.01%	790
2019 Q4	$19K	Buy	+89	New	+$18K	﹤0.01%	596

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

IndexIQ Advisors's VRTX Position: Q1 2022 in Review

IndexIQ Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q1 2022, selling an estimated $93.7K and leaving 17,542 shares worth $4.58M. The position accounts for 0.16% of the portfolio, ranked #123.

IndexIQ Advisors first reported a position in VRTX in Q4 2019 and has held it in 10 quarters since. 1,071 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

IndexIQ Advisors held 17,542 shares of Vertex Pharmaceuticals worth $4.58M as of Q1 2022.
IndexIQ Advisors sold 395 Vertex Pharmaceuticals shares in Q1 2022, an estimated $93.7K.
Vertex Pharmaceuticals made up 0.16% of IndexIQ Advisors's portfolio in Q1 2022, its #123 holding.
IndexIQ Advisors first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 10 quarters since.
1,071 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.